Capeller B, Caffier H, Sütterlin M W, Dietl J
Department of Gynaecology, University of Würzburg, Josef-Schneider-Str. 4, 97080 Würzburg, Germany.
Anticancer Res. 2003 Mar-Apr;23(2A):1011-5.
The osteoclast-specific active TRAP 5b isoform is detectable in serum and claimed to be a specific marker of bone resorption. The present study was undertaken to evaluate the usefulness of TRAP 5b as a serum marker of bone resorption in breast cancer patients with bone metastases.
TRAP 5b serum levels were measured in 192 samples from patients with breast cancer with and without bone metastases and in 53 healthy pre- and postmenopausal women using the enzyme immunoassay Bone-TRAP.
Serum levels of TRAP 5b were significantly higher in patients with breast cancer and clinical signs of bone metastases before therapy than in healthy women. There was also a significant difference between patients with bone metastases before and during bisphosphonate therapy, indicating a reduction of bone alteration under this treatment. The subgroup with progression of bone metastases under bisphosphonate therapy showed the highest difference in TRAP 5b concentrations compared to patients with stable disease.
Serum TRAP 5b levels are elevated in patients with bone metastases and breast cancer. The TRAP 5b levels decline under bisphosphonate therapy when no progression is detectable. When progress of the bone metastases occurs, TRAP 5b levels rise again. Therefore, active TRAP 5b seems to be a useful serum marker for bone metastases in breast cancer patients, especially to detect progressive disease under bisphosphonate treatment. Further studies with larger numbers of patients are required to confirm these data.
破骨细胞特异性活性TRAP 5b亚型在血清中可检测到，据称是骨吸收的特异性标志物。本研究旨在评估TRAP 5b作为骨转移乳腺癌患者骨吸收血清标志物的实用性。
使用酶免疫分析法Bone-TRAP检测192例有或无骨转移的乳腺癌患者以及53例绝经前后健康女性的192份样本中的TRAP 5b血清水平。
治疗前有骨转移临床体征的乳腺癌患者血清TRAP 5b水平显著高于健康女性。双膦酸盐治疗前和治疗期间有骨转移的患者之间也存在显著差异，表明该治疗可减轻骨改变。与病情稳定的患者相比，双膦酸盐治疗期间骨转移进展的亚组TRAP 5b浓度差异最大。
骨转移乳腺癌患者血清TRAP 5b水平升高。在无可检测到的进展时，双膦酸盐治疗下TRAP 5b水平下降。当骨转移进展时，TRAP 5b水平再次升高。因此，活性TRAP 5b似乎是乳腺癌患者骨转移的有用血清标志物，尤其是用于检测双膦酸盐治疗下的疾病进展。需要更多患者的进一步研究来证实这些数据。
